science
GNI Group to Acquire Ayumi Pharmaceutical Holdings for ¥44.8 Billion
GNI Group Co., Ltd. signed an agreement to purchase all shares of Ayumi Pharmaceutical Holdings Co., Ltd. from its current owners. The deal values the target at approximately ¥44.8 billion and is expected to raise the combined company's fiscal 2026 revenue to about ¥65.2 billion.
Jun 7, 7:41 PM·1m read2 sources
prnewswire.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
, Ltd. , Ltd. from its existing shareholders. The transaction values Ayumi at roughly ¥44.8 billion and will turn the company into a wholly owned subsidiary of GNI Group. The purchase broadens GNI Group's commercial operations inside Japan and creates a larger pharmaceutical platform.
Company officials said the combined business will speed the introduction of new therapies, biosimilars, and internally developed products to Japanese patients.
Group projects that the merged companies will generate combined revenue of approximately ¥65.2 billion in fiscal 2026. The transaction also brings new shareholders into GNI Group, including Blackstone, Toho, and Hisamitsu. Ying Luo, President and CEO of GNI Group, said the acquisition marks a milestone in the company's long-term strategy to build a cross-Pacific biopharmaceutical business.
The statement noted that Ayumi's domestic sales network and pain-management products will be integrated into GNI Group's existing operations.
